A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

NCT06465446 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

202

Enrollment

OTHER

Sponsor class

Conditions

Classic Hodgkin Lymphoma

Interventions

BIOLOGICAL: Tislelizumab
BIOLOGICAL: IMM01
DRUG: Bendamustine
DRUG: Gemcitabine

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.